Newsroom

NEW
DxI 9000 Access Immunoassay Analyzer

Featured News

Beckman Coulter’s DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced today, ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays. Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.

Read more
DxI 9000 Access Immunoassay Analyzer

Featured News

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient- friendly, Blood-based Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays. 

Read more

News Releases

Learn more about the latest news and happenings at Beckman Coulter. 

See all news releases  


  • April 16, 2024 

    Beckman Coulters DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

    Read more
  • March 12, 2024 

    Beckman Coulter and Fujirebio Expand Partnership to Develop Patient- friendly, Blood-based Neurodegenerative Disease Diagnostics

    Read more
  • February 6, 2024

    Beckman Coulter Appoints Kevin O'Reilly as New President

    Read more
  • January 30, 2024

    Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

    Read more
Global Public Relations
Name Jeff Tarmy
Address Beckman Coulter World Headquarters
Brea California
Phone +1-617-467-7537

Stay Connected